Elevated CRP and IL6 Levels Predict Severe Cardiovascular Outcomes in COVID-19 Patients-Reference-Cited by-同舟云学术

Elevated CRP and IL6 Levels Predict Severe Cardiovascular Outcomes in COVID-19 Patients

Published:2024-05-17 Issue:2 Volume:9 Page:
ISSN:2714-7444
Container-title:Academia Open
language:
Short-container-title:acopen

Author:

Al Khuzaie Ali Abdel Moneim Mohammed Hussain,Jabbar Enas Abdul Kareem,Albadry Bushra Jabbar

Abstract

This study explores the association between C-reactive protein (CRP) and interleukin 6 (IL-6) levels and cardiovascular complications in COVID-19 patients. Utilizing an ELISA kit for IL-6 and standard tests for CRP, we analyzed 192 samples, finding higher infection rates among the 50-69 age group, with significant prevalence of morbid obesity. Results showed a strong correlation between elevated CRP and IL-6 levels and the severity of cardiovascular complications, particularly in critical cases. These findings suggest that monitoring these biomarkers could be crucial for early intervention and managing cardiovascular risks in COVID-19 patients, potentially improving patient outcomes in clinical settings. Highlights: Biomarker Correlation: Elevated CRP and IL-6 levels are linked to severe cardiovascular complications in COVID-19 patients. Risk Management: Monitoring these biomarkers helps in early intervention and managing cardiovascular risks. Demographic Insights: The highest infection and complication rates are among the 50-69 age group with significant obesity. Keywords: COVID-19, Cardiovascular Complications, CRP, IL-6, Biomarker Monitoring

Publisher

Universitas Muhammadiyah Sidoarjo

Reference48 articles.

1. I. M. Artika, A. K. Dewantari, and A. Wiyatno, “Molecular biology of coronaviruses: current knowledge,” Heliyon, vol. 6, no. 8, p. e04743, 2020, doi: 10.1016/j.heliyon.2020.e04743.

2. M. G. Hossain, A. Javed, S. Akter, and S. Saha, “SARS-CoV-2 host diversity: An update of natural infections and experimental evidence,” J. Microbiol. Immunol. Infect., vol. 54, no. 2, pp. 175–181, 2021, doi: 10.1016/j.jmii.2020.06.006.

3. B. Grubišić et al., “Molecular Mechanisms Responsible for Diabetogenic Effects of COVID-19 Infection—Induction of Autoimmune Dysregulation and Metabolic Disturbances,” Int. J. Mol. Sci., vol. 24, no. 14, 2023, doi: 10.3390/ijms241411576.

4. K. Tyagi et al., “Neurological manifestations of SARS-CoV-2: complexity, mechanism and associated disorders,” Eur. J. Med. Res., vol. 28, no. 1, pp. 1–25, 2023, doi: 10.1186/s40001-023-01293-2.

5. N. Vishwakarma, R. B. Goud, M. P. Tirupattur, and L. C. Katwa, “The Eye of the Storm: Investigating the Long-Term Cardiovascular Effects of COVID-19 and Variants,” Cells, vol. 12, no. 17, 2023, doi: 10.3390/cells12172154.